Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE phase 3 trial of pegzilarginase in arginase 1 deficiency
2018-004837-34Phase 3Completed
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Apr 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arginase 1 deficiency (ARG1-D) comparing Pegzilarginase with Placebo (2 arms). Primary endpoint: Change from baseline in plasma arginine after 24 weeks of study treatment. Started Apr 2019; status: completed.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)
Beyond the preview
Go deeper on 2018-004837-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004837-34.